

# Hampig Raphael Kourie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3593834/publications.pdf>

Version: 2024-02-01

109  
papers

1,246  
citations

471509

17  
h-index

454955

30  
g-index

111  
all docs

111  
docs citations

111  
times ranked

2733  
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2 in gastric adenocarcinoma: where do we stand today?. <i>Personalized Medicine</i> , 2022, 19, 67-78.	1.5	1
2	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2022, 14, 155-167.	2.0	7
3	Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?. <i>Future Oncology</i> , 2022, 18, 519-522.	2.4	0
4	BRAF: a biomarker not to be missed in glioblastoma. <i>Personalized Medicine</i> , 2022, 19, 79-82.	1.5	0
5	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	1.8	6
6	The rapidly evolving landscape of advanced gastric cancer therapy. <i>Future Oncology</i> , 2022, , .	2.4	1
7	Polygenic and Network-based studies in risk identification and demystification of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 427-438.	3.1	7
8	Talazoparib in <i>BRCA</i> -mutated advanced breast cancer: is earlier better?. <i>Pharmacogenomics</i> , 2022, 23, 487-492.	1.3	0
9	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	4.4	14
10	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	5.7	7
11	In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. <i>Future Oncology</i> , 2021, 17, 11-12.	2.4	0
12	Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care?. <i>Future Oncology</i> , 2021, 17, 229-233.	2.4	0
13	Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK. <i>Personalized Medicine</i> , 2021, 18, 5-7.	1.5	1
14	Will advanced cholangiocarcinoma become a targetable malignancy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103233.	4.4	2
15	Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?. <i>Immunotherapy</i> , 2021, 13, 459-463.	2.0	2
16	<i>NTRK</i> genes and cancer: when arresting the fusion underlies the treatment. <i>Epigenomics</i> , 2021, 13, 561-564.	2.1	0
17	Targeting glioblastoma: from dream to reality. <i>Biomarkers in Medicine</i> , 2021, 15, 385-388.	1.4	3
18	Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors. <i>Pharmacogenomics</i> , 2021, 22, 247-250.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?. <i>Biomarkers in Medicine</i> , 2021, 15, 609-613.	1.4	2
20	Molecular profiling of basal cell carcinomas in young patients. <i>BMC Medical Genomics</i> , 2021, 14, 187.	1.5	6
21	Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?. <i>Pharmacogenomics</i> , 2021, 22, 619-628.	1.3	2
22	KRAS-targeted therapies in advanced solid cancers: drug the undruggable?. <i>Pharmacogenomics</i> , 2021, 22, 587-590.	1.3	5
23	YouTube as a source of information on breast cancer in the Arab world. <i>Supportive Care in Cancer</i> , 2021, 29, 8009-8017.	2.2	11
24	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021, 22, 791-803.	1.3	2
25	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021, 13, 953-964.	2.0	5
26	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	2.0	16
27	An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. <i>Leukemia Research Reports</i> , 2021, 15, 100245.	0.4	1
28	After decades, RAS mutation has finally become a therapeutic target. <i>Personalized Medicine</i> , 2021, 18, 523-525.	1.5	0
29	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. <i>Pharmacogenomics</i> , 2021, 22, 1237-1250.	1.3	1
30	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103524.	4.4	7
31	Knowledge and behavior of Lebanese parents regarding melanoma prevention in public and private school children. <i>Melanoma Management</i> , 2021, 8, MMT59.	0.5	0
32	Is ramucirumab still the only second-line treatment in metastatic gastric cancer?. <i>Pharmacogenomics</i> , 2020, 21, 1203-1206.	1.3	1
33	The psychological challenges for oncological patients in times of COVID-19 pandemic: telemedicine, a solution?. <i>Future Oncology</i> , 2020, 16, 2265-2268.	2.4	21
34	Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience. <i>Bulletin Du Cancer</i> , 2020, 107, 738-740.	1.6	10
35	Bioethical considerations for cancer patient care during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 2779-2781.	2.4	2
36	Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. <i>Pharmacogenomics</i> , 2020, 21, 957-962.	1.3	0

#	ARTICLE	IF	CITATIONS
37	The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon. <i>Complementary Therapies in Medicine</i> , 2020, 53, 102534.	2.7	3
38	Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. <i>Future Oncology</i> , 2020, 16, 1225-1227.	2.4	84
39	The future of cancer research after COVID-19 pandemic: recession?. <i>Future Oncology</i> , 2020, 16, 1493-1495.	2.4	11
40	Acute myeloid leukemia transformed to a targetable disease. <i>Future Oncology</i> , 2020, 16, 961-972.	2.4	12
41	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , 2020, 9, CNS55.	3.0	2
42	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 721-727.	1.3	5
43	Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?. <i>Pharmacogenomics</i> , 2020, 21, 731-733.	1.3	2
44	A rare case of acute myeloid leukemia with t(12;19)(q13;q13). <i>Leukemia Research Reports</i> , 2020, 14, 100216.	0.4	1
45	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020, 21, 221-230.	1.3	16
46	The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience. <i>Future Oncology</i> , 2020, 16, 1157-1160.	2.4	12
47	Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102972.	4.4	178
48	The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 615-617.	2.4	27
49	Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas. <i>Immunotherapy</i> , 2020, 12, 1149-1152.	2.0	0
50	Ocular and orbital side effects of ALK inhibitors: a review article. <i>Future Oncology</i> , 2019, 15, 1939-1945.	2.4	13
51	&lt;p&gt;Triple-negative breast cancer: current perspective on the evolving therapeutic landscape&lt;/p&gt;. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	2.6	117
52	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. <i>Future Oncology</i> , 2019, 15, 1505-1524.	2.4	12
53	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019, 11, 1409-1422.	2.0	28
54	PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 1539-1541.	1.4	9

#	ARTICLE	IF	CITATIONS
55	TRK inhibitors: toward an era of agnostic targeted therapies in oncology. <i>Pharmacogenomics</i> , 2019, 20, 927-929.	1.3	5
56	Do immune-related adverse events correlate with response to immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 257-259.	2.0	17
57	Skin adverse events in recently approved targeted therapies in solid malignancies. <i>Future Oncology</i> , 2019, 15, 331-343.	2.4	3
58	FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. <i>Future Oncology</i> , 2019, 15, 1947-1950.	2.4	0
59	Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 457-460.	2.0	5
60	Seizures in cancer patients: a vast spectrum of etiologies. <i>Future Neurology</i> , 2019, 14, FNL30.	0.5	1
61	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. <i>Future Oncology</i> , 2019, 15, 533-541.	2.4	21
62	Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13045-e13045.	1.6	1
63	Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13544-e13544.	1.6	0
64	Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?. <i>Immunotherapy</i> , 2018, 10, 345-347.	2.0	9
65	Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?. <i>Future Oncology</i> , 2018, 14, 677-680.	2.4	1
66	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , 2018, 14, 829-835.	2.4	6
67	Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?. <i>Immunotherapy</i> , 2018, 10, 163-165.	2.0	9
68	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018, 105, 857-861.	1.6	8
69	Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?. <i>Immunotherapy</i> , 2018, 10, 823-826.	2.0	0
70	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , 2018, 14, 2097-2102.	2.4	4
71	New developments in the management of head and neck cancer &ndash; impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 295-303.	2.0	55
72	Urging medical students to publish: Advantages, disadvantages and new challenges. <i>Bulletin Du Cancer</i> , 2018, 105, 626-628.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017, 13, 1097-1103.	2.4	1
74	Physical long-term side-effects in young adult cancer survivors: germ cell tumors model. <i>Current Opinion in Oncology</i> , 2017, 29, 229-234.	2.4	6
75	Negative predictive biomarkers of checkpoint inhibitors in hyper-progressive tumors. <i>Biomarkers in Medicine</i> , 2017, 11, 819-821.	1.4	3
76	Is gut microbiome a predictive marker to response to immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2017, 9, 865-866.	2.0	5
77	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017, 13, 1999-2006.	2.4	2
78	Electronic patient-reported outcomes: a revolutionary strategy in cancer care. <i>Future Oncology</i> , 2017, 13, 2397-2399.	2.4	9
79	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. <i>Immunotherapy</i> , 2017, 9, 647-657.	2.0	19
80	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 105-111.	1.6	4
81	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	2.0	11
82	Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 303.	0.8	17
83	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	1.6	3
84	Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality. <i>World Journal of Gastroenterology</i> , 2017, 23, 3017.	3.3	9
85	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017, 8, 145.	2.3	10
86	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. <i>World Journal of Clinical Oncology</i> , 2017, 8, 425-428.	2.3	5
87	Efficacy and tolerability of second-line intra-arterial 5FU or mitomycin C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15061-e15061.	1.6	0
88	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 10124.	3.3	27
89	Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 745.	2.0	21
90	Managing Hodgkin lymphoma without chemotherapy: a novel, yet “welcomed” challenge. <i>Future Oncology</i> , 2016, 12, 1435-1437.	2.4	3

#	ARTICLE	IF	CITATIONS
91	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016, 34, 794-796.	2.6	17
92	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. <i>Colorectal Cancer</i> , 2016, 5, 91-93.	0.8	1
93	Metastatic gastric cancer treatment: Second line and beyond. <i>World Journal of Gastroenterology</i> , 2016, 22, 3069.	3.3	30
94	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 297.	2.0	8
95	Road map for pain management in pancreatic cancer: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 599.	2.0	44
96	Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 2679-81.	1.2	9
97	Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy. <i>Case Reports in Ophthalmological Medicine</i> , 2015, 2015, 1-4.	0.5	6
98	Anal cancer treatment: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 2294.	3.3	48
99	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. <i>Journal of Bone Oncology</i> , 2015, 4, 77-79.	2.4	9
100	EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. <i>Cancer Epidemiology</i> , 2015, 39, 1099-1102.	1.9	15
101	Successful Eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e23-e24.	1.5	4
102	EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18506-e18506.	1.6	2
103	Optimum chemotherapy for the management of advanced biliary tract cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 4121.	3.3	10
104	Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 8473.	3.3	5
105	Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5899-5902.	1.2	2
106	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3294-8.	0.5	3
107	Optimum chemotherapy in the management of metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 2352.	3.3	19
108	Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, 450-457.	0.7	34

#	ARTICLE	IF	CITATIONS
109	Outcome of Breast Cancer Screening: A Lebanese Single Institution Experience. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9471-9473.	1.2	1